| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 28, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 26,250 | Jul 30, 2025, 05:57 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 28, 2025 | Sale | $20.46 | 3,250 | 66,504 | 23,065 | Jul 30, 2025, 05:57 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 10, 2025 | Option/RSU Exercise | $2.48 | 1,000 | 2,480 | 24,000 | Jul 14, 2025, 05:07 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 10, 2025 | Sale | $22.66 | 1,000 | 22,655 | 23,000 | Jul 14, 2025, 05:07 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jun 27, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 26,250 | Jul 01, 2025, 04:42 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jun 27, 2025 | Sale | $20.91 | 3,250 | 67,956 | 23,198 | Jul 01, 2025, 04:42 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jun 13, 2025 | Option/RSU Exercise | $2.48 | 3,000 | 7,440 | 26,000 | Jun 17, 2025, 04:24 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jun 13, 2025 | Sale | $22.55 | 3,000 | 67,655 | 23,000 | Jun 17, 2025, 04:24 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | May 27, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 26,250 | May 29, 2025, 05:38 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | May 27, 2025 | Sale | $16.18 | 3,250 | 52,593 | 23,000 | May 29, 2025, 05:38 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Apr 28, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 26,250 | Apr 30, 2025, 06:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Apr 28, 2025 | Sale | $18.69 | 3,250 | 60,738 | 23,069 | Apr 30, 2025, 06:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 27, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 26,250 | Mar 31, 2025, 07:37 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 27, 2025 | Sale | $21.33 | 3,250 | 69,321 | 23,000 | Mar 31, 2025, 07:37 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 24, 2025 | Sale | $22.50 | 1,000 | 22,504 | 23,000 | Mar 26, 2025, 07:37 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 24, 2025 | Option/RSU Exercise | $2.48 | 1,000 | 2,480 | 24,000 | Mar 26, 2025, 07:37 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 04, 2025 | Option/RSU Exercise | $2.48 | 10,000 | 24,800 | 23,000 | Mar 06, 2025, 06:02 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Feb 27, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 16,250 | Mar 03, 2025, 08:07 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Feb 27, 2025 | Sale | $20.41 | 3,250 | 66,327 | 13,000 | Mar 03, 2025, 08:07 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Feb 05, 2025 | Sale | $22.52 | 1,000 | 22,524 | 13,000 | Feb 07, 2025, 07:06 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Feb 05, 2025 | Option/RSU Exercise | $2.48 | 1,000 | 2,480 | 14,000 | Feb 07, 2025, 07:06 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jan 27, 2025 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 16,250 | Jan 29, 2025, 07:21 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jan 27, 2025 | Sale | $21.59 | 3,250 | 70,178 | 13,000 | Jan 29, 2025, 07:21 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Dec 13, 2024 | Option/RSU Exercise | $2.48 | 13,000 | 32,240 | 13,000 | Jan 07, 2025, 04:43 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jan 03, 2025 | Option/RSU Exercise | $2.48 | 1,000 | 2,480 | 14,000 | Jan 07, 2025, 04:43 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jan 03, 2025 | Sale | $25.04 | 1,000 | 25,039 | 13,000 | Jan 07, 2025, 04:43 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Dec 27, 2024 | Option/RSU Exercise | $2.48 | 3,350 | 8,308 | 3,350 | Dec 31, 2024, 05:18 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Dec 27, 2024 | Sale | $22.15 | 3,350 | 74,219 | 0 | Dec 31, 2024, 05:18 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Dec 30, 2024 | Option/RSU Exercise | $2.48 | 900 | 2,232 | 900 | Dec 31, 2024, 05:18 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Dec 30, 2024 | Sale | $22.51 | 900 | 20,255 | 0 | Dec 31, 2024, 05:18 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Nov 27, 2024 | Sale | $24.89 | 5,250 | 130,688 | 1,000 | Dec 02, 2024, 05:18 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Nov 27, 2024 | Option/RSU Exercise | $2.48 | 5,250 | 13,020 | 5,250 | Dec 02, 2024, 05:18 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 28, 2024 | Option/RSU Exercise | $2.48 | 6,250 | 15,500 | 6,250 | Oct 30, 2024, 06:04 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 28, 2024 | Sale | $28.56 | 6,250 | 178,485 | 650 | Oct 30, 2024, 06:04 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 18, 2024 | Option/RSU Exercise | $2.48 | 814 | 2,019 | 814 | Oct 22, 2024, 04:19 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 18, 2024 | Sale | $30.00 | 814 | 24,422 | 0 | Oct 22, 2024, 04:19 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 04, 2024 | Option/RSU Exercise | $2.48 | 10,218 | 25,341 | 10,218 | Oct 08, 2024, 06:56 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 04, 2024 | Sale | $27.51 | 10,218 | 281,079 | 0 | Oct 08, 2024, 06:56 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 07, 2024 | Option/RSU Exercise | $2.48 | 1,270 | 3,150 | 2,000 | Oct 08, 2024, 06:56 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 07, 2024 | Sale | $27.51 | 1,270 | 34,935 | 0 | Oct 08, 2024, 06:56 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 01, 2024 | Sale | $27.54 | 521 | 14,347 | 0 | Oct 03, 2024, 06:44 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Oct 01, 2024 | Option/RSU Exercise | $2.48 | 521 | 1,292 | 521 | Oct 03, 2024, 06:44 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sep 27, 2024 | Option/RSU Exercise | $2.48 | 4,250 | 10,540 | 4,250 | Oct 01, 2024, 07:53 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sep 27, 2024 | Sale | $24.27 | 4,250 | 103,161 | 0 | Oct 01, 2024, 07:53 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sep 30, 2024 | Option/RSU Exercise | $2.48 | 2,000 | 4,960 | 2,000 | Oct 01, 2024, 07:53 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Sep 30, 2024 | Sale | $25.33 | 2,000 | 50,668 | 0 | Oct 01, 2024, 07:53 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Aug 27, 2024 | Option/RSU Exercise | $2.48 | 4,250 | 10,540 | 4,250 | Aug 29, 2024, 06:36 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Aug 27, 2024 | Sale | $22.54 | 4,250 | 95,782 | 0 | Aug 29, 2024, 06:36 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 31, 2024 | Option/RSU Exercise | $2.48 | 991 | 2,458 | 991 | Aug 02, 2024, 07:23 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 31, 2024 | Sale | $27.53 | 991 | 27,281 | 0 | Aug 02, 2024, 07:23 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 29, 2024 | Option/RSU Exercise | $2.48 | 5,250 | 13,020 | 5,250 | Jul 31, 2024, 07:31 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 29, 2024 | Sale | $26.68 | 5,250 | 140,052 | 61 | Jul 31, 2024, 07:31 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 12, 2024 | Option/RSU Exercise | $2.48 | 3,000 | 7,440 | 3,000 | Jul 16, 2024, 05:34 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jul 12, 2024 | Sale | $25.07 | 3,000 | 75,195 | 0 | Jul 16, 2024, 05:34 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jun 27, 2024 | Option/RSU Exercise | $2.48 | 4,250 | 10,540 | 4,250 | Jul 01, 2024, 08:03 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jun 27, 2024 | Sale | $22.57 | 4,250 | 95,922 | 2,970 | Jul 01, 2024, 08:03 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | May 28, 2024 | Sale | $23.18 | 4,250 | 98,530 | 2,344 | May 30, 2024, 05:54 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | May 28, 2024 | Option/RSU Exercise | $2.48 | 4,250 | 10,540 | 4,250 | May 30, 2024, 05:54 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | May 03, 2024 | Option/RSU Exercise | $2.48 | 1,000 | 2,480 | 1,000 | May 07, 2024, 06:58 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | May 03, 2024 | Sale | $22.50 | 1,000 | 22,500 | 0 | May 07, 2024, 06:58 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Apr 29, 2024 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 3,250 | May 01, 2024, 07:02 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Apr 29, 2024 | Sale | $16.97 | 3,250 | 55,165 | 0 | May 01, 2024, 07:02 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Apr 11, 2024 | Option/RSU Exercise | $2.48 | 14,000 | 34,720 | 14,000 | Apr 15, 2024, 07:04 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Apr 11, 2024 | Sale | $24.72 | 14,000 | 346,149 | 10,223 | Apr 15, 2024, 07:04 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 27, 2024 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 3,250 | Mar 29, 2024, 05:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Mar 27, 2024 | Sale | $18.25 | 3,250 | 59,302 | 182 | Mar 29, 2024, 05:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Feb 27, 2024 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 3,250 | Feb 29, 2024, 05:27 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Feb 27, 2024 | Sale | $16.97 | 3,250 | 55,163 | 0 | Feb 29, 2024, 05:27 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jan 29, 2024 | Option/RSU Exercise | $2.48 | 3,250 | 8,060 | 3,250 | Jan 31, 2024, 09:20 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | CHIEF FINANCIAL OFFICER | Jan 29, 2024 | Sale | $15.81 | 3,250 | 51,388 | 0 | Jan 31, 2024, 09:20 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 29, 2023 | Sale | $15.00 | 20 | 300 | 0 | Jan 02, 2024, 07:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Jan 02, 2024 | Option/RSU Exercise | $2.48 | 9,383 | 23,270 | 9,383 | Jan 02, 2024, 07:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Jan 02, 2024 | Sale | $15.01 | 9,383 | 140,839 | 0 | Jan 02, 2024, 07:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 28, 2023 | Option/RSU Exercise | $2.48 | 2,467 | 6,118 | 2,467 | Jan 02, 2024, 07:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 28, 2023 | Sale | $15.07 | 2,467 | 37,188 | 0 | Jan 02, 2024, 07:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 29, 2023 | Option/RSU Exercise | $2.48 | 20 | 50 | 20 | Jan 02, 2024, 07:59 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 26, 2023 | Option/RSU Exercise | $2.48 | 100 | 248 | 100 | Dec 27, 2023, 05:26 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 26, 2023 | Sale | $15.00 | 100 | 1,500 | 0 | Dec 27, 2023, 05:26 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 22, 2023 | Option/RSU Exercise | $2.48 | 1,030 | 2,554 | 1,030 | Dec 27, 2023, 05:26 PM |
| ELVN | | Enliven Therapeutics, Inc. | Benjamin Hohl | Chief Financial Officer | Dec 22, 2023 | Sale | $15.07 | 1,030 | 15,525 | 0 | Dec 27, 2023, 05:26 PM |
